Tecovirimat Patent Expiration

Tecovirimat is Used for treating human smallpox disease caused by variola virus in adults and pediatric patients. It was first introduced by Siga Technologies Inc in its drug Tpoxx on Jul 13, 2018.


Tecovirimat Patents

Given below is the list of patents protecting Tecovirimat, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tpoxx US10576165 ST-246 liquid formulations and methods Aug 02, 2031 Siga Technologies
Tpoxx US11890270 Polymorphic forms of ST-246 and methods of preparation Aug 08, 2032 Siga Technologies
Tpoxx US7737168 Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases Sep 04, 2031 Siga Technologies
Tpoxx US8039504 Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases Jul 23, 2027 Siga Technologies
Tpoxx US8124643 Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases Jun 18, 2024

(Expired)

Siga Technologies
Tpoxx US8530509 Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases Jun 18, 2024

(Expired)

Siga Technologies
Tpoxx US8802714 Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases Jun 18, 2024

(Expired)

Siga Technologies
Tpoxx US9233097 ST-246 liquid formulations Aug 02, 2031 Siga Technologies
Tpoxx US9339466 Polymorphic forms of ST-246 and methods of preparation Mar 23, 2031 Siga Technologies
Tpoxx US9907859 ST-246 liquid formulations and methods Aug 02, 2031 Siga Technologies


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳